Top Markets
#1 Islamic Coin Islamic Coin +151.51%
#2 Akedo Akedo +62.71%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.49%
#5 Velvet Velvet +46.29%
#6 Cross Cross +37.03%
#7 Black Phoenix Black Phoenix +34.20%
#8 Cap Cap +20.04%
#9 DoubleZero DoubleZero +15.02%
#10 Humanity Humanity +11.35%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
Ganga Pharmaceuticals Limited Ganga Pharmaceuticals Limited

Ganga Pharmaceuticals Limited

GANGAPHARM
株式のランク #39130
Ganga Pharmaceuticals Ltd. is actively involved in the production and trade of... Ganga Pharmaceuticals Ltd. is actively involved in the production and trade of pharmaceutical products and related goods. The company primarily concentrates on the formulation, marketing, and supply of Ayurvedic medicines in bulk quantities. Notable products in its portfolio include Ampachan Vati, Khadira Vati, and Nirmalaya Churna. The firm offers a range of Ayurvedic solutions designed to address health issues such as acidity, dandruff, oxidative stress, constipation, oral hygiene, diarrhea, ear ailments, women's health, and joint discomfort. Brijmohan C. Sharma founded the organization in 1974, and its main corporate office is located in Mumbai, India.
株価
$0.13243053
最終同期: 2026-03-16
時価総額
$637.36K
変化（1日）
0.00%
変化（1年）
-20.46%
国
IN
取引 Ganga Pharmaceuticals Limited (GANGAPHARM)

カテゴリー

Healthcare
Ganga Pharmaceuticals Limited（GANGAPHARM）の利益
2026 時点の利益 TTM: 0
Ganga Pharmaceuticals Limited の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Ganga Pharmaceuticals Limited の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
$1.35B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
$26.37M -
US